FOLH1 and prostate carcinoma: Targeting the prostate-specific membrane antigen (PSMA) with 177Lu-labeled PSMA-specific tracers has emerged as a very viable therapeutic treatment for prostate cancer, according to Ruigrok et al. (2022) [35].